 Genocea Biosciences, Inc. GNCA, a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced the filing of an Investigational New Drug IND Application with the U.S. Food and Drug Administration FDA to begin a Phase 12a clinical study of GEN-011 in a range of tumor types, with a focus on patients who have failed standard-of-care checkpoint inhibitor therapy. The GEN-011 trial will evaluate patient safety, T cell proliferation and persistence, and clinical activity, with preliminary data expected mid-2021. 